Belzutifan: a novel therapy for von Hippel–Lindau disease
Belzutifan: a novel therapy for von Hippel–Lindau disease
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associated with VHL disease.
Alternative Titles
Full title
Belzutifan: a novel therapy for von Hippel–Lindau disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2626890614
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2626890614
Other Identifiers
ISSN
1759-5061
E-ISSN
1759-507X
DOI
10.1038/s41581-022-00544-5
